Development for a new, heat-resistant malaria vaccine has begun. A partnership beteen GlaxoSmithKline adnd the Bill and Melinda Gates Foundation worth $1.8 million is aimed at developing a malaria drug that does not require refrigeration.
There are roughly 660,000 malaria deaths a year--many victims are children in Sub-Saharan Africa where many are without access to vaccinations. A major issue in these areas is the heat, as many drugs are not heat-stable. Companies are now striving to break the "cold chain" to provide necessary vaccines across the world.